Canabo Continues to Increase Market Share

Since inception, Canabo Medical Inc. (CMM.V: TSX Venture) (CAMDF) has seen significant demand for its services and continues to open new clinics across Canada. Today, the company announced the opening of its 16th clinic in Kelowna, British Columbia, and this facility will be led by Dr. Chemanthi Kalen.

In December, Canabo entered a strategic partnership with Peak Medical Group, which operates partner clinics for Canabo throughout Alberta. Canabo announced that Peak recently opened its second location in Edmonton to accommodate for increasing patient demand.

This development comes less than two weeks after Canabo released the results of a groundbreaking study where 40% of patients who were prescribed medical cannabis to treat pain and anxiety eliminated the use of benzodiazepines within 90 days. The number of patients who stopped using benzodiazepines increased to 45% within a year of treatment.

Invictus MD’s AB Laboratories Enters Into An Agreement With Canopy Growth

This morning Invictus MD Strategies announced that AB Laboratories Inc., a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations, will provide their unique products in Canopy Growth Corporation’s curated CraftGrow line on Tweed Main Street’s online store, that brings high quality cannabis grown by a diverse set of producers. People want variety, they want different choices, and Tweed Main Street is an opportunity in the legal market where patients can see what is available through the convenience of an online store.

With Canada on the global stage as it moves closer to making history by being the first G-7 nation to legalize and regulate access to cannabis for the recreational market and the expected demand that will result, Invictus MD will continue to focus on building out AB Labs and AB Ventures Inc.’s production capacity in Ontario and successfully acquiring Acreage Pharms Ltd.’s production facility in Alberta. After the successful development and acquisition of these facilities, Invictus MD anticipates that it will have the capacity to supply more than 50,000 kg of cannabis by 2020. This creates an attractive value proposition in the burgeoning cannabis market.

GW’s Epidiolex Steps Closer To Approval

If cannabis does not have medical benefits, then why did the American Academy of Neurology (AAN) issue a press release highlighting positive results from one of GW Pharmaceuticals’ (GWPH) studies?

During treatment period, patients taking the low and high dosage of Epidiolex saw a significant decrease in monthly drop seizures (37% and 42%, respectively) when compared to patients taking a placebo (17%).

New data from key secondary endpoints were also encouraging. The results showed a 50% or greater reduction in monthly drop seizures in patients receiving the low and high dosage of Epidiolex, when compared the patients taking a placebo

Another encouraging statistic is related to the improvement in the patient’s overall condition. 66% of patients/caregivers reported an improvement in overall condition at the lower dose while 57% reported an improvement in overall condition at the higher dose. This is better than the 44% reported by patients/caregivers for patients taking the placebo.

GW has continued to prove government agencies and officials to inaccurate when it comes to assessing the medical benefits of cannabis. The company is the only Nasdaq-traded biotech firm focused on developing treatments from the actual cannabis plant. Unlike Zynerba Pharmaceuticals (ZYNE) which develop treatments from synthetic cannabis; GW uses the actual plant and the benefits of this are shown through its continued success in FDA trials.

Read the rest of the article